

Attorney Docket No.:

GCI-0019

Inventors:

Lotfi Chouchane

Serial No.:

10/040,707

Filing Date:

January 7, 2002

Examiner:

Not Yet Assigned

Group Art Unit:

3736

Title:

Method of Identifying and Managing Increased Risk of Breast Carcinoma Associated with Polymorphisms in MHC

Genes

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, P.O. Box 2327, Arlington, VA 22202-0327

On this date: April 17, 2002

Kathleen A. Tyrrell, R

stration No. 38,350

Assistant Commissioner for Patents Box 2327 Arlington, VA 22202-0237

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information

Disclosure Statement is being filed either within three

APR % \$ 2002
TECHNOLOGY CENTER RO760

months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

45

- () In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, therefore:
 - () Certification in Accordance with §1.97(e) is set forth below; or
 - () The fee of \$180.00 as set forth in \$1.17(p) is attached.
- () In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with \$1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in \$1.17(i)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith with the exception of AB, AG and AJ. In view of the voluminous nature of these publications and the likelihood that the Examiner may have a

publications and the likelihood that the Examiner may have a copy available to him or her, a copy has not been included herewith. However, if the Examiner does not have a copy available, Applicant will endeavor to supply one at the Examiner's request.

4

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. ______, filed ______, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

- () The relevance of the listed references in a foreign language is as stated in the specification at pages @@.
- (XX) All listed references are in the English language.

Respectfully submitted,

Kathleen A. Tyrrel

Registration No. 38,350

Date: April 17, 2002

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053 (856) 810-1515



Sheet 03 of 03

| Form PTO-1449 Modified | | | | - 13 | Docket No | Serial No. 10/040,707 | | | | |
|---|----|--------------|--------------|---------|-------------------------------|---------------------------------------|------|-----------------------|-------------|--|
| List of Patents and Publications Cited by Applicant (Use several sheets if necessary) | | | | | Applicant Lotfi Chouchane | | | | | |
| U.S. Department of Commerce Patent and Trademark Office | | | | | Filing Da Janaury 7 | Group 3736 | | | | |
| U. S. PATENT DOCUMENTS | | | | | | | | | | |
| Examiner | | Document | Date | | Name | | Clas | Subclass | | |
| | | | | | | | | | | |
| | | | | | | | - | | | |
| | | | | _ | | | | | | |
| | | | | \perp | | | | - 15 02 | | |
| 3 | | | | + | | | | | 3 (1) | |
| | | | " | + | | | | 0 6 | 3 1 3 23 | |
| | | | | + | | - 100 20 20 | | | 300 | |
| | | | | | | · · · · · · · · · · · · · · · · · · · | | 7:3736 | | |
| | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | |
| Examiner Initial | | Document No. | | Da | te | Country | | Translation YES NO | | |
| | AA | 0 200 362 | | 12 | 2-10-86 EPO | | X. | | | |
| | AB | 0 201 184 | | 12 | 2-17-86 EPO | | | x | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | | | | |



Sheet 01 of 03

| | | & TRADE. | | - SIICCC | | | |
|---|-------|---|-----------------------------|--------------------------|--|--|--|
| Form | n PTO | -1449 Modified | Docket No. GCI-0019 | Serial No. 10/040,707 | | | |
| List of Patents and Publications Cited by Applicant (Use several sheets if necessary) | | | Applicant Lofti Chouchane | | | | |
| U.S. Department of Commerce | | | Filing Date January 7, 2002 | Group 3736 | | | |
| OTHER DOC | UMEN' | TS (Including Author, | Title, Date, Perti | nent Pages, Etc.) | | | |
| | AA | Cabrera et al., "Polymorphism in Tumor Necrosis Factor Genes Associated with Mucocutaneous Leishmaniasis", J. Exp. Med. 1995 182:1259-64 | | | | | |
| | AB | Coligan et al. Current Protocols in Immunology 1(2):Chapter 5 1991 | | | | | |
| | AC | Cooney et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro", Science 1988 241:456-459 | | | | | |
| | AD | Beal and Dervan, "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation", Science 1991 251:1360-1363 | | | | | |
| | AE | Milner and Campbell, "Structure and expression of the three MHC-linked HSP70 genes", Immunogenetics 1990 32:242-251 | | | | | |
| | AF | Lee et al., "Complexes formed by (pyrimidine), (purine), DNAs on lowering the pH are three-stranded", Nucleic Acids Res. 1979 6:3073-3091 | | | | | |
| | AG | O'Connor in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. 1988 | | | | | |
| | АН | Sargent et al., "Human major histocompatibility complex contains genes for the major heat shock protein HSP70", Proc. Natl. Acad. Sci. 1989 86:1968-1972 | | | | | |
| | AI | Wilson et al., "Single base polymorphism in the human Tumour Necrosis Factor alpha (TNFα) gene detectable by NcoI restriction of PCR product", Human Mol. Genet. 1993 1:353 | | | | | |
| EXAMINER | | | DATE CONSIDERED | | | | |
| | | | | | | | |



Sheet 02 of 03

| Form PTO-1449 Modified | | | Docket No. GCI-0019 | | Serial No. 10/040,707 | | | | | |
|------------------------|-----------------------------|---|------------------------------|---------|-----------------------|---------------------------|------|-------------|--|--|
| Ci | ted | s and Publications by Applicant sheets if necessary) | Applicant Lotfi Chouchane | | | | | | | |
| | U.S. Department of Commerce | | | 002 | Group 3736 | | | | | |
| OTHER DOC | UMENI | S (Including Author, | Title, Date, | Perti | nent Pag | jes, | Etc | .) | | |
| | AJ | Chapter 20, Gene Therapy an Approaches, (and references Strachan and A. P. Read, B. | s cited therein) i | n Human | Molecular | | | т. | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | TEC: | | <u>[</u> F] | | |
| | | | * | | | DLC3 | P2 2 | 0 | | |
| | | | <u>,</u> | | | / CEN | ග | 1 1 1 1 | | |
| | | | | | | TECHN OLCGY CEN EN F.C769 | 2002 | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | <u> </u> | | | | |
| | | | | | | | | į | | |
| EXAMINER | | | DATE CONSID | ERED | • | | | | | |